Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA4 | P22748 | 9/20 | 0.44 |
| ▸ | CA7 | P43166 | 9/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648066 | 0.77 | CA12 (0.49) | CA12CA9CA1CA2CA4 | |
| SCHEMBL10636828 | 0.67 | CA12 (0.62) | CA12CA9CA1CA2CA4 | |
| SCHEMBL11120453 | 0.67 | HTT (0.42) | HTTERN1TDP1PKM | |
| SCHEMBL6313062 | 0.65 | PTGS2 (0.62) | CA9HTTERN1TDP1PKM | |
| SCHEMBL29212380 | 0.64 | CA12 (0.51) | CA12CA9CA1CA2CA4 | |
| SCHEMBL10981831 | 0.64 | HTT (0.56) | HTTERN1TDP1PKM | |
| Potassium Ion SCHEMBL6313612 | 0.64 | ERN1 (0.57) | HTTERN1TDP1ALOX5PKM | |
| SCHEMBL7929923 | 0.64 | HTT (0.56) | HTTERN1TDP1ALOX5PKM | |
| SCHEMBL7929928 | 0.64 | HTT (0.67) | HTTERN1TDP1ALOX5PKM | |
| SCHEMBL4946627 | 0.64 | ERN1 (0.72) | CA12CA9CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631559-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20060122173-A1 | Il-8 receptor antagonists | BUSCH-PETERSEN JAKOB | 2006-06-08 | — | — | US | disclosed |
| EP-1631559-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005000231-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122173-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CA12 3361/4885CA9 1990/4885CA1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.